Alkermes Plc
NASDAQ:ALKS

Watchlist Manager
Alkermes Plc Logo
Alkermes Plc
NASDAQ:ALKS
Watchlist
Price: 28.5 USD -2.3% Market Closed
Market Cap: 4.7B USD

Relative Value

The Relative Value of one ALKS stock under the Base Case scenario is 35.23 USD. Compared to the current market price of 28.5 USD, Alkermes Plc is Undervalued by 19%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALKS Relative Value
Base Case
35.23 USD
Undervaluation 19%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
60
vs Industry
68
Median 3Y
3.2
Median 5Y
3.3
Industry
7.9
Forward
3.1
vs History
23
vs Industry
9
Median 3Y
14
Median 5Y
-27.1
Industry
23.7
Forward
18.9
vs History
90
vs Industry
12
Median 3Y
11.5
Median 5Y
24.2
Industry
22
vs History
82
vs Industry
3
Median 3Y
12.5
Median 5Y
16.3
Industry
23.8
vs History
92
vs Industry
25
Median 3Y
3.6
Median 5Y
3.6
Industry
3.3
vs History
77
vs Industry
61
Median 3Y
2.6
Median 5Y
2.8
Industry
8.3
Forward
2.4
vs History
79
vs Industry
62
Median 3Y
3.1
Median 5Y
3.4
Industry
10.1
vs History
46
vs Industry
11
Median 3Y
8.7
Median 5Y
9.3
Industry
6.4
Forward
9.3
vs History
22
vs Industry
10
Median 3Y
10
Median 5Y
-24
Industry
7
Forward
13.8
vs History
90
vs Industry
13
Median 3Y
9.4
Median 5Y
21.5
Industry
8.3
vs History
82
vs Industry
9
Median 3Y
10.4
Median 5Y
12.8
Industry
6.5
vs History
42
vs Industry
34
Median 3Y
3.3
Median 5Y
3.2
Industry
5.7

Multiples Across Competitors

ALKS Competitors Multiples
Alkermes Plc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IE
Alkermes Plc
NASDAQ:ALKS
4.7B USD 3.1 13.9 9.2 10
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 809 907.8 -160 693.5 -195 133.1 -192 906.4
US
Abbvie Inc
NYSE:ABBV
394.7B USD 6.6 168.1 16.3 23.1
US
Amgen Inc
NASDAQ:AMGN
170.9B USD 4.8 24.4 17.7 17.7
US
Gilead Sciences Inc
NASDAQ:GILD
149.5B USD 5.1 18.4 12.4 12.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.8B USD 9.8 31.2 22.9 23.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 083.7 -531.7 -579 -563.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.1B USD 5.5 17.1 16.2 18.4
AU
CSL Ltd
ASX:CSL
89.1B AUD 3.8 19.7 13.2 16.5
NL
argenx SE
XBRU:ARGX
45.9B EUR 15 35.2 60.8 62.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.4B USD 16.3 1 202.7 158 191.6
P/E Multiple
Earnings Growth PEG
IE
Alkermes Plc
NASDAQ:ALKS
Average P/E: 170.1
13.9
-12%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 693.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.1
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.4
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.4
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.2
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
9%
1.9
AU
CSL Ltd
ASX:CSL
19.7
11%
1.8
NL
argenx SE
XBRU:ARGX
35.2
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 202.7
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IE
Alkermes Plc
NASDAQ:ALKS
Average EV/EBITDA: 36.3
9.2
2%
4.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 133.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.7
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.9
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
11%
1.5
AU
CSL Ltd
ASX:CSL
13.2
8%
1.7
NL
argenx SE
XBRU:ARGX
60.8
839%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
158
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IE
Alkermes Plc
NASDAQ:ALKS
Average EV/EBIT: 41.8
10
-7%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 906.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.7
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.4
13%
1.4
AU
CSL Ltd
ASX:CSL
16.5
11%
1.5
NL
argenx SE
XBRU:ARGX
62.5
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
191.6
N/A N/A